Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies - Takeaways - MDSpire

Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies

  • By

  • Franciska Otaner

  • Vratko Himic

  • Luis O. Vargas

  • Matthew Abikenari

  • Neelesh Pandey

  • Shayndhan Sivanathan

  • Olivia Kalmanson

  • Aparna Govindan

  • Diane Jung

  • Dagoberto Estevez-Ordonez

  • Amy Wang

  • Sanjeeva Jeyaretna

  • Ashish H. Shah

  • Ricardo J. Komotar

  • Bradley Gampel

  • Christine Dinh

  • Michael E. Ivan

  • May 16, 2026

Share

  • 1

    Vestibular schwannomas are benign tumors of the vestibulocochlear nerve, causing hearing loss and other neurological symptoms.

  • 2

    Approximately 90% of vestibular schwannomas are sporadic, with most showing somatic NF2 loss linked to tumor behavior.

  • 3

    Genetic and epigenetic factors, including merlin loss and chromatin remodeling, significantly influence vestibular schwannoma biology.

  • 4

    Current therapies for vestibular schwannomas, including bevacizumab, show limited efficacy, highlighting the need for improved treatment strategies.

  • 5

    Integrating genetic and epigenetic insights into clinical practice may enhance prognosis and treatment selection for vestibular schwannoma patients.

Original Source(s)

Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies

  • by Franciska Otaner, Vratko Himic, Luis O. Vargas, Matthew Abikenari, Neelesh Pandey, Shayndhan Sivanathan, Olivia Kalmanson, Aparna Govindan, Diane Jung, Dagoberto Estevez-Ordonez, Amy Wang, Sanjeeva Jeyaretna, Ashish H. Shah, Ricardo J. Komotar, Bradley Gampel, Christine Dinh, Michael E. Ivan

  • May 16, 2026

Related Content